Gilles Crochet
YOU?
Author Swipe
View article: Large B-cell lymphoma: The LYSA pragmatic guidelines
Large B-cell lymphoma: The LYSA pragmatic guidelines Open
View article: 264 | CD3XCD20 BISPECIFIC ANTIBODIES IN TRANSFORMED WALDENSTRÖM MACROGLOBULINEMIA/LYMPHOPLASMACYTIC LYMPHOMA
264 | CD3XCD20 BISPECIFIC ANTIBODIES IN TRANSFORMED WALDENSTRÖM MACROGLOBULINEMIA/LYMPHOPLASMACYTIC LYMPHOMA Open
View article: 160 | VERLen: TAFASITAMAB, LENALINOMIDE, PLUS RITUXIMAB IN FRONTLINE DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS OVER 80 Y/O OR OLDER, A LYSA PHASE 2 TRIAL
160 | VERLen: TAFASITAMAB, LENALINOMIDE, PLUS RITUXIMAB IN FRONTLINE DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS OVER 80 Y/O OR OLDER, A LYSA PHASE 2 TRIAL Open
View article: Efficacy of tazemetostat in combination with R-CHOP in elderly patients newly diagnosed with diffuse large B cell lymphoma: results of the EpiRCHOP phase II study of the LYSA
Efficacy of tazemetostat in combination with R-CHOP in elderly patients newly diagnosed with diffuse large B cell lymphoma: results of the EpiRCHOP phase II study of the LYSA Open
View article: Salvage monotherapy with venetoclax after failure from a single course of standard induction chemotherapy for acute myeloid leukaemia
Salvage monotherapy with venetoclax after failure from a single course of standard induction chemotherapy for acute myeloid leukaemia Open
View article: Comment to "Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphoma": chimeric antigen receptor T-cell therapy remains effective after exposure to bispecific antibodies
Comment to "Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphoma": chimeric antigen receptor T-cell therapy remains effective after exposure to bispecific antibodies Open
Not available.
View article: How to treat localized Hodgkin lymphoma?
How to treat localized Hodgkin lymphoma? Open
Purpose of review We aim to summarize the current knowledge on the management of early-stage classical Hodgkin lymphoma, with a focus on conventional strategies, incorporation of immunotherapies and exploration of novel prognostic markers.…
View article: Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma
Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma Open
In this retrospective study, chimeric antigen receptor T cells remained effective in patients with relapsed/refractory large B-cell lymphoma after prior exposure to bispecific antibodies (BsAbs) targeting different antigens. These results …
View article: Results of the EpiRCHOP Phase II Study on the Efficacy of Tazemetostat in Combination with R-CHOP in Elderly Patients Newly Diagnosed with Diffuse Large B Cell Lymphoma: A LYSA Study
Results of the EpiRCHOP Phase II Study on the Efficacy of Tazemetostat in Combination with R-CHOP in Elderly Patients Newly Diagnosed with Diffuse Large B Cell Lymphoma: A LYSA Study Open
View article: LATE EFFECTS AFTER TREATMENT OF HODGKIN LYMPHOMA, A SINGLE CENTRE EXPERIENCE
LATE EFFECTS AFTER TREATMENT OF HODGKIN LYMPHOMA, A SINGLE CENTRE EXPERIENCE Open
Introduction: Classical Hodgkin Lymphoma (cHL) has an incredibly high survival rate, exceeding 80% at 10 years. Continuous improvement in treatment strategies led to an increased number of survivors in the community. Most common complicati…
View article: Une paralysie isolée du nerf oculomoteur commun révélant un lymphome primitif du système nerveux central
Une paralysie isolée du nerf oculomoteur commun révélant un lymphome primitif du système nerveux central Open